PharmaShots Weekly Snapshots (March 20

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency

Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE

Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer Drug Rigosertib

Date: Mar 24, 2023 | Tags: Onconova Therapeutics, Pangea Biomed, Rigosertib, Nivolumab, Biomarkers, Squamous Cell Carcinoma, ENLIGHT platform, Biotech

Boehringer Ingelheim’s Spevigo (spesolimab) Receives the Health Canada’s Marketing Authorization for Generalized Pustular Psoriasis

Date: Mar 24, 2023 | Tags: Boehringer Ingelheim, Spevigo, spesolimab, Generalized Pustular Psoriasis, Regulatory, Health Canada, Marketing Authorization

AbbVie Reports P-III Study (INSPIRE) Results of Skyrizi (risankizumab) in P-III Induction Study (INSPIRE) for Ulcerative Colitis

Date: Mar 24, 2023 | Tags: AbbVie, Skyrizi, Risankizumab, Ulcerative Colitis, Clinical Trial, P-III, INSPIRE, Induction Study

AstraZeneca’s Calquence (acalabrutinib) Receives the NMPA’s Approval for Mantle Cell Lymphoma

Date: Mar 24, 2023 | Tags: AstraZeneca, Calquence, acalabrutinib, Mantle Cell Lymphoma, Regulatory, NMPA, Approval

Macomics Signs a Worldwide Drug Discovery Collaboration Agreement with Ono to Discover and Develop Macrophage-Targeting Antibody Therapy for Cancer

Date: Mar 24, 2023 | Tags: Macomics, Ono, Macrophage-targeting, Antibody, Cancer, ENIGMACT macrophage drug discovery platform, Pharma

Ono Pharmaceutical’s Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the MFDS Approval as 1L Treatment of Esophageal Squamous Cell Carcinoma in South Korea

Date: Mar 23, 2023 | Tags: Ono Pharmaceutical, Opdivo, nivolumab, Yervoy, ipilimumab, Esophageal Squamous Cell Carcinoma, Regulatory, MFDS

Ancora Heart Reports 12 Month Results of AccuCinch System for the Treatment of Patients with Heart Failure

Date: Mar 23, 2023 | Tags: Ancora Heart, AccuCinch System, Heart Failure, Clinical Trial, MedTech

Regeneron and Sanofi Report P-III Trial (BOREAS) Results of Dupixent (dupilumab) for Chronic Obstructive Pulmonary Disease

Date: Mar 23, 2023 | Tags: Regeneron, Sanofi, Dupixent, dupilumab, Chronic Obstructive Pulmonary Disease, Clinical Trial, P-III, BOREAS Trial

Incyte’s Zynyz (retifanlimab-Dlwr) Receives the US FDA’s Approval for Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma

Date: Mar 23, 2023 | Tags: Incyte, Zynyz, retifanlimab-Dlwr, Merkel Cell Carcinoma, Regulatory, US, FDA, Approval

Biohaven Acquires Rights for BHV-8000 to Treat Immune-Mediated Brain Disorders

Date: Mar 23, 2023 | Tags: Biohaven, BHV-8000, TLL-041, Immune-Mediated Brain Disorders, Pharma

Dewpoint Therapeutics Collaborated with Novo Nordisk to Identify Small Molecule Drugs for Insulin Resistance and Diabetes Progression

Date: Mar 23, 2023 | Tags: Dewpoint Therapeutics, Novo Nordisk, AI technology platform, Insulin Resistance, Diabetes Progression, Pharma

TaiGen Entered into an Exclusive License Agreement with Joincare to Develop and Commercialize TG-1000 in China

Date: Mar 22, 2023 | Tags: TaiGen, Joincare, TG-1000, China, Pharma

Medtronic Collaborated with NVIDIA to Advance the Development of AI in the Healthcare Industry

Date: Mar 22, 2023 | Tags: Medtronic, NVIDIA, AI, NVIDIA Holoscan & NVIDIA IGX, GI Genius, colorectal cancer, DigiHealth

Jacobio Entered into a Clinical Collaboration with Merck to Evaluate JAB-BX102 + Keytruda (pembrolizumab) for Solid Tumors

Date: Mar 22, 2023 | Tags: Jacobio, Merck, JAB-BX102, Keytruda, pembrolizumab, pablizumab, Solid Tumors, Pharma

Lumicell Reports the NDA Submission of Lumisight Optical Imaging Agent to the US FDA for the Detection and Removal of Intraoperative Breast Cancer

Date: Mar 22, 2023 | Tags: Lumicell, Lumisight Optical Imaging Agent, Intraoperative Breast Cancer, Regulatory, US, FDA, NDA

Altimmune Reports 24 Week Interim Analysis Results of Pemvidutide in P-II Trial (MOMENTUM) and P-Ib Trial for Obesity and Type 2 Diabetes

Date: Mar 22, 2023 | Tags: Altimmune, Pemvidutide, Obesity, Type 2 Diabetes, Clinical Trial, P-II, MOMENTUM, P-Ib Trial

Kite Reports P-III Study (ZUMA-7) Results of Yescarta for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma

Date: Mar 22, 2023 | Tags: Kite, Yescarta, Large B-cell Lymphoma, Clinical Trial, P-III, ZUMA-7 Study

OrsoBio Reports the First Patient Dosing of TLC-3595 in P-IIa Clinical Trial for the Treatment of Type 2 Diabetes

Date: Mar 21, 2023 | Tags: OrsoBio, TLC-3595, Type 2 Diabetes, Clinical Trial, P-II Trial

Selecta and Sobi Report P-III Trial (DISSOLVE I & II) Results of SEL-212 for Chronic Refractory Gout

Date: Mar 21, 2023 | Tags: Selecta, Sobi, SEL-212, Chronic Refractory Gout, Clinical Trial, P-III, DISSOLVE I & II Trial

Regeneron’s Dupixent (dupilumab) Receives EC’s Approval as First Targeted Medicine for Severe Atopic Dermatitis

Date: Mar 21, 2023 | Tags: Regeneron, Dupixent, dupilumab, Atopic Dermatitis, Regulatory, EC, Approval

CHARM Therapeutics Collaborated with BMS to Advance Small Molecule Drug Discovery Programs

Date: Mar 21, 2023 | Tags: Bristol Myers Squibb, CHARM Therapeutics, Small Molecule, Drug Discovery, DragonFold deep learning platform, Pharma

Gilead Exercises its Option to License Nurix’s NX-0479 for Cancer

Date: Mar 21, 2023 | Tags: Gilead, Nurix, NX-0479, GS-6791 Cancer, Biotech

BioNTech Signs an Exclusive Worldwide License and Collaboration Agreement with OncoC4 to Co-Develop and Commercialize ONC-392

Date: Mar 21, 2023 | Tags: BioNTech, OncoC4, ONC-392, Solid Tumor, Non-small cell lung cancer, Pharma

Coya Therapeutics Signs an Agreement with Dr. Reddy’s Laboratories to License its Proposed Biosimilar Abatacept to Develop and Commercialize COYA 302

Date: Mar 20, 2023 | Tags: Coya Therapeutics, Dr. Reddy’s Laboratories, Abatacept, COYA 302, neurodegenerative diseases, Pharma

UCB Reports P-III Studies (BE HEARD I) & (BE HEARD II) Results of Bimekizumab for the Treatment of Hidradenitis Suppurativa

Date: Mar 20, 2023 | Tags: UCB, Bimekizumab, Hidradenitis Suppurativa, Clinical Trial, P-III, BE HEARD I, BE HEARD II Trial

Takeda Reports P-IIb Trial Results TAK-279 for the Treatment of Plaque Psoriasis

Date: Mar 20, 2023 | Tags: Takeda, TAK-279, Plaque Psoriasis, Clinical Trial, P-IIb Trial

DermaSensor Presents Pooled Analysis Results from the (DERM-ASSESS III) & (DERM-SUCCESS) Clinical Studies of Skin Cancer Detection Device

Date: Mar 20, 2023 | Tags: DermaSensor, Device, Skin Cancer, Clinical Trial, DERM-ASSESS III, DERM-SUCCESS Clinical, Clinical Trial, MedTech